HUTCHMED (China) Limited (HCM)
USD 14.89
(8.53%)
USD 14.89
(8.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 837.99 Million USD | 96.52% |
| 2022 | 426.4 Million USD | 19.73% |
| 2021 | 356.12 Million USD | 56.21% |
| 2020 | 227.97 Million USD | 11.27% |
| 2019 | 204.89 Million USD | -4.31% |
| 2018 | 214.1 Million USD | -11.23% |
| 2017 | 241.2 Million USD | 11.63% |
| 2016 | 216.08 Million USD | 21.25% |
| 2015 | 178.2 Million USD | 94.09% |
| 2014 | 91.81 Million USD | 99.72% |
| 2013 | 45.97 Million USD | -76.47% |
| 2012 | 195.39 Million USD | 17.05% |
| 2011 | 166.92 Million USD | 24.1% |
| 2010 | 134.5 Million USD | 21.18% |
| 2009 | 110.99 Million USD | 27.62% |
| 2008 | 86.97 Million USD | 33.58% |
| 2007 | 65.1 Million USD | 29.1% |
| 2006 | 50.43 Million USD | 33.21% |
| 2005 | 37.86 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 152.84 Million USD | 0.18% |
| 2024 Q2 | 152.84 Million USD | 0.0% |
| 2023 Q2 | 266.43 Million USD | 0.0% |
| 2023 Q4 | 152.56 Million USD | 0.0% |
| 2023 FY | 837.99 Million USD | 96.52% |
| 2023 Q1 | 266.43 Million USD | 137.51% |
| 2023 Q3 | 152.56 Million USD | -42.74% |
| 2022 FY | 426.4 Million USD | 19.73% |
| 2022 Q4 | 112.18 Million USD | 0.0% |
| 2022 Q3 | 112.18 Million USD | -44.48% |
| 2022 Q2 | 202.04 Million USD | 100.0% |
| 2022 Q1 | 101.02 Million USD | -26.88% |
| 2021 Q4 | 138.16 Million USD | 39.02% |
| 2021 FY | 356.12 Million USD | 56.21% |
| 2021 Q3 | 99.38 Million USD | 31.1% |
| 2021 Q1 | 81.55 Million USD | 34.57% |
| 2021 Q2 | 75.8 Million USD | -7.05% |
| 2020 Q4 | 60.6 Million USD | 0.0% |
| 2020 FY | 227.97 Million USD | 11.27% |
| 2020 Q2 | 55.19 Million USD | 7.03% |
| 2020 Q1 | 51.57 Million USD | -2.41% |
| 2020 Q3 | 60.6 Million USD | 9.8% |
| 2019 Q1 | 52.16 Million USD | -55.05% |
| 2019 Q2 | 50.02 Million USD | -4.1% |
| 2019 FY | 204.89 Million USD | -4.31% |
| 2019 Q3 | 49.34 Million USD | -1.36% |
| 2019 Q4 | 52.84 Million USD | 7.08% |
| 2018 Q3 | 58.81 Million USD | 17.97% |
| 2018 Q2 | 49.85 Million USD | -4.75% |
| 2018 Q1 | 52.33 Million USD | -53.54% |
| 2018 FY | 214.1 Million USD | -11.23% |
| 2018 Q4 | 116.05 Million USD | 97.33% |
| 2017 FY | 241.2 Million USD | 11.63% |
| 2017 Q3 | 57.3 Million USD | -54.73% |
| 2017 Q4 | 112.65 Million USD | 96.58% |
| 2017 Q1 | 63.29 Million USD | 13.46% |
| 2017 Q2 | 126.58 Million USD | 100.0% |
| 2016 Q1 | 52.25 Million USD | -7.15% |
| 2016 FY | 216.08 Million USD | 21.25% |
| 2016 Q2 | 52.25 Million USD | 0.0% |
| 2016 Q4 | 55.78 Million USD | 0.0% |
| 2016 Q3 | 55.78 Million USD | 6.74% |
| 2015 Q3 | 56.19 Million USD | 36.26% |
| 2015 FY | 178.2 Million USD | 94.09% |
| 2015 Q4 | 56.28 Million USD | 0.15% |
| 2015 Q2 | 41.24 Million USD | 0.0% |
| 2015 Q1 | 41.24 Million USD | 22.9% |
| 2014 FY | 91.81 Million USD | 99.72% |
| 2014 Q4 | 33.55 Million USD | 20.18% |
| 2014 Q2 | 15.16 Million USD | 0.0% |
| 2014 Q1 | 15.16 Million USD | 216.88% |
| 2014 Q3 | 27.92 Million USD | 84.15% |
| 2013 Q3 | 14.2 Million USD | 61.89% |
| 2013 Q1 | 8.77 Million USD | 43.29% |
| 2013 Q2 | 8.77 Million USD | 0.0% |
| 2013 FY | 45.97 Million USD | -76.47% |
| 2013 Q4 | 4.78 Million USD | -66.32% |
| 2012 FY | 195.39 Million USD | 17.05% |
| 2012 Q3 | 6.12 Million USD | 0.0% |
| 2012 Q4 | 6.12 Million USD | 0.0% |
| 2011 FY | 166.92 Million USD | 24.1% |
| 2010 FY | 134.5 Million USD | 21.18% |
| 2009 FY | 110.99 Million USD | 27.62% |
| 2008 FY | 86.97 Million USD | 33.58% |
| 2007 FY | 65.1 Million USD | 29.1% |
| 2006 FY | 50.43 Million USD | 33.21% |
| 2005 FY | 37.86 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | -47.856% |
| Embecta Corp. | 1.12 Billion USD | 25.232% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | -72.139% |
| Dynavax Technologies Corporation | 232.28 Million USD | -260.765% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -620.339% |
| Pacira BioSciences, Inc. | 674.97 Million USD | -24.152% |
| PainReform Ltd. | - USD | -Infinity% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -1556.681% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -3378.215% |
| SCYNEXIS, Inc. | 140.14 Million USD | -497.968% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -43353.477% |
| Cosmos Health Inc. | 53.37 Million USD | -1469.966% |
| Journey Medical Corporation | 79.18 Million USD | -958.333% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -3378.215% |
| Safety Shot Inc | 202.67 Thousand USD | -413379.548% |
| Alpha Teknova, Inc. | 36.68 Million USD | -2184.372% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | -80.459% |
| Bright Green Corporation | 401.49 Thousand USD | -208621.74% |
| Procaps Group, S.A. | 409.92 Million USD | -104.43% |
| Theratechnologies Inc. | 81.76 Million USD | -924.9% |
| Harrow Health, Inc. | 130.19 Million USD | -543.659% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -6480.283% |
| Biofrontera Inc. | 34.07 Million USD | -2359.567% |
| DURECT Corporation | 8.54 Million USD | -9703.451% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -37.937% |
| Cronos Group Inc. | 88.84 Million USD | -843.258% |
| OptiNose, Inc. | 70.98 Million USD | -1080.496% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | -89.278% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -12766.217% |
| Organogenesis Holdings Inc. | 433.14 Million USD | -93.471% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -6741.618% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -2018.7% |
| Radius Health, Inc. | 2.88 Billion USD | 70.925% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -2493.723% |
| ProPhase Labs, Inc. | 44.38 Million USD | -1788.066% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 17.656% |
| Procaps Group S.A. | 409.92 Million USD | -104.43% |
| Alvotech | 91.43 Million USD | -816.507% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -64262.442% |
| Viatris Inc. | 15.42 Billion USD | 94.568% |
| Rockwell Medical, Inc. | 83.61 Million USD | -902.247% |
| Aytu BioPharma, Inc. | 81 Million USD | -934.541% |
| SIGA Technologies, Inc. | 139.91 Million USD | -498.925% |
| Tilray Brands, Inc. | 788.94 Million USD | -6.218% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -553.354% |
| Shineco, Inc. | 9.8 Million USD | -8449.391% |
| PetIQ, Inc. | 1.1 Billion USD | 23.954% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -6983225.0% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 55.593% |
| Alimera Sciences, Inc. | 80.75 Million USD | -937.718% |
| Silver Spike Investment Corp. | 11.72 Million USD | -7048.861% |
| Assertio Holdings, Inc. | 152.06 Million USD | -451.065% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -14292.703% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -4711.385% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -77751.645% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -2896.814% |
| Hempacco Co., Inc. | 4.04 Million USD | -20613.648% |
| Talphera, Inc. | 651 Thousand USD | -128624.885% |
| Alvotech | 91.43 Million USD | -816.507% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | -164.679% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 35.361% |
| Currenc Group, Inc. | 53.25 Million USD | -1473.549% |
| Kamada Ltd. | 144.75 Million USD | -478.893% |
| Indivior PLC | 1.09 Billion USD | 23.33% |
| Evoke Pharma, Inc. | 5.18 Million USD | -16075.62% |
| Flora Growth Corp. | 76.07 Million USD | -1001.601% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -77751.645% |
| Evolus, Inc. | 202.08 Million USD | -314.676% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | -30.044% |
| Akanda Corp. | 2.16 Million USD | -38695.316% |